State opioid settlement funds refer to the collective pool of money—more than $50 billion nationally—that states, cities, counties, and tribal governments are receiving from a series of legal settlements and bankruptcy resolutions with opioid manufacturers, distributors, and pharmacy chains found to have contributed to the opioid crisis. The major agreements include the 2021 Distributor and Janssen settlements, and subsequent 2022–2024 settlements with CVS, Walgreens, Walmart, Allergan, Teva, and Kroger.
Unlike a federal grant program with a single application process, opioid settlement money is allocated according to state-specific legal and administrative frameworks: roughly 35 states have enacted legislation establishing formal spending structures, and about 40 states have published memoranda of understanding with local governments defining how funds are divided among a state share, a statewide abatement fund, and direct payments to cities and counties. Settlement terms require that funds be used for opioid remediation—prevention, treatment, recovery support, harm reduction, and related public health infrastructure—and that they supplement rather than replace existing funding for these purposes. Recent state legislation tracked by ASTHO shows states continuing to formalize governance structures, from Georgia's expanded Behavioral Health Reform Commission to Mississippi's new Opioid Settlement Fund Advisory Council.
Because governance, allocation formulas, and priority-setting processes are set independently by each state, there is no single national opioid-settlement application—an organization interested in these funds needs to identify and work through their specific state's abatement council, health department, or attorney general's office. For healthcare organizations operating across multiple states, this makes opioid settlement funding one of the more administratively fragmented—but also one of the largest and most flexible—funding sources in this glossary, particularly for behavioral health and substance-use treatment access initiatives in rural communities where treatment capacity gaps are most acute.
They're the collective pool of more than $50 billion nationally that states, cities, counties, and tribal governments are receiving from legal settlements with opioid manufacturers, distributors, and pharmacy chains, including the 2021 Distributor and Janssen settlements and subsequent settlements with CVS, Walgreens, Walmart, and others.
Unlike a federal grant program, allocation is state-specific: roughly 35 states have enacted legislation establishing formal spending structures, and about 40 states have published agreements dividing funds among a state share, a statewide abatement fund, and direct payments to cities and counties.
Funds must go toward opioid remediation—prevention, treatment, recovery support, and harm reduction—and must supplement rather than replace existing funding. States have used funds for naloxone distribution, provider training, recovery housing, and Medicaid room-and-board coverage gaps.
There is no single national application. Organizations must identify and work through their specific state's abatement council, health department, or attorney general's office.
Every term here points to the same gap in healthcare access. See how the CareStation closes it.
Talk to Our Team
